NOZINAN
BIOPHARM
Identification
- Active ingredient (INN)
- LEVOMEPROMAZINE
- Internal code
- 16 D 058
- Country of Origin
- Algeria
- Pharmaceutical form
- Scored Film-coated Tablet
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/20
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Description
A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine.
It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604).
Indications
For the treatment of psychosis, particular those of schizophrenia, and manic phases of bipolar disorder.
Pharmacodynamics
Methotrimeprazine is a phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine.
It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604).
Absorption
Methotrimeprazine has an incomplete oral bioavailability, because it undergoes considerable first-pass-metabolism in the liver.
Oral bioavailability is approximately 50-60%.
Metabolism
Methotrimeprazine is metabolized in the liver and degraded to a sulfoxid-, a glucuronid.
- and a demethyl-moiety.
Half-life
Approximately 20 hours.
Adverse Effects
Improve decision support & research outcomes With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
View sample adverse effects data in our new Data Library! See the data Improve decision support & research outcomes with our structured adverse effects data.
Toxicity
Symptoms of overdose include convulsions, spastic movements, and coma.